-
Product Insights
Contrast Agents Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Contrast Agents Pipeline Market Report Overview The Contrast Agents pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments · Positron Emitting Tomography Contrast Agents · Magnetic Resonance Imaging (MRI) Contrast Agents · Gadolinium-based MRI Contrast Agents...
-
Company Profile
LMI Aerospace Inc – Company Profile
LMI Aerospace Inc (LMI), a subsidiary of Sonaca SA, supplies structural assemblies, design engineering services, kits, and components for the aerospace, defense, and technology industries. The company provides manufacturing, engineering and value-added services to corporate, commercial, regional, and military aircraft markets. It also provides prototyping, testing and design capabilities to customers to support new product development and in-service aircraft. It manufactures components and assemblies for laser equipment, which is used in the manufacturing of semiconductor equipment, cable assemblies, electronic and...
Add to Basket -
Company Profile
Lantheus Medical Imaging Inc – Company Profile
Lantheus Medical Imaging Inc (Lantheus Medical), a subsidiary of Lantheus Holdings, Inc., develops, manufactures and commercializes diagnostic imaging agents and products. The company offers commercial products including ultrasound contrast agent and medical radiopharmaceuticals in a range of imaging modalities. Its products include DEFINITY, TechneLite, Xenon 133, Neurolite, , Thallium-201, Cardiolite and Gallium-67. The company’s product pipeline include 1095 and LMI 1195. The company offers its products to nuclear physicians, internal medicine physicians, radiologists, technologists and sonographers, integrated delivery networks, hospitals,...
Add to Basket -
Product Insights
Lantheus Medical Imaging Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Lantheus Medical Imaging Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Lantheus Medical Imaging Inc (Lantheus Medical), a subsidiary of Lantheus Holdings, Inc., develops, manufactures and commercializes diagnostic imaging agents and products. The company offers commercial products including ultrasound contrast agent and medical radiopharmaceuticals in a range of imaging modalities. Its products include DEFINITY, TechneLite, Xenon 133, Neurolite, , Thallium-201, Cardiolite and Gallium-67. Its product pipeline include 1095 and...
-
Product Insights
Chamber of Pharma Ghana/ LMI Hldg – Dawa Industrial Zone Pharmaceutical Park – Greater Accra
Equip yourself with the essential tools needed to make informed and profitable decisions with our Chamber of Pharma Ghana/ LMI Hldg - Dawa Industrial Zone Pharmaceutical Park - Greater Accra report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash...
-
Product Insights
Net Present Value Model: Branaplam
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Branaplam Drug Details Branaplam hydrochloride (LMI-070)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – branaplam hydrochloride
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry branaplam hydrochloride Drug Details Branaplam hydrochloride (LMI-070) is under development for the treatment of Huntington...